Related Experiment Videos
Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis
A Schnabel1, E Reinhold-Keller, V Willmann
1Department of Clinical Rheumatology, University of Lübeck, Germany.
Abstract:
The objective of the present study was to assess the rate of side-effects and dose-limiting toxicity in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX) at an initial dose of 15 or 25 mg/week. One hundred and eighty-five patients with active RA were enrolled into a prospective non-blind trial over 12 months and randomized to start at a dose of 15 mg/week with subsequent increases if necessary (group A) or 25 mg/week with subsequent dose reductions according to effect (group B). With 168 patients eligible for evaluation 74% of patient in group A and 73% of patients in group B were on MTX after 12 months. Withdrawal due to side-effects amounted to 16% of patients in group A and 18% in group B, and decreases in dose due to side-effects amounted to 10% in group A and 9% in group B. The higher dose of MTX elicited a significantly higher rate of gastrointestinal side-effects (28% versus 17%, P < 0.05) and a tendency towards a higher rate of liver enzyme elevations (47% versus 39%). The frequencies of other side-effects did not differ significantly between the groups. We concluded that starting MTX treatment at a dose of 25 mg/week was associated with a higher rate of minor but not major toxicity as compared with 15 mg/week. With this profile of tolerability it is possible to examine the therapeutic potential of MTX doses exceeding 15 mg/week.
Insights
Starting methotrexate (MTX) at 25 mg/week for rheumatoid arthritis (RA) causes more minor side-effects than 15 mg/week. Higher MTX doses are tolerable and warrant further investigation for RA treatment potential.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Methotrexate (MTX) is a cornerstone therapy for rheumatoid arthritis (RA).
- Optimizing MTX dosing is crucial for balancing efficacy and tolerability.
- Understanding the toxicity profile at different initial doses is essential for patient management.
Purpose of the Study:
- To compare the rates of side-effects and dose-limiting toxicity in RA patients initiating MTX at 15 mg/week versus 25 mg/week.
- To evaluate the tolerability and safety of higher initial MTX doses in active RA.
Main Methods:
- A prospective, non-blind trial involving 185 patients with active RA.
- Patients were randomized to initiate MTX at 15 mg/week (Group A) or 25 mg/week (Group B).
- Dose adjustments were made based on efficacy and tolerability over a 12-month period.
Main Results:
- 74% and 73% of patients in Group A and B, respectively, remained on MTX after 12 months.
- Withdrawal due to side-effects was similar between groups (16% vs. 18%).
- The 25 mg/week dose showed a significantly higher rate of gastrointestinal side-effects (28% vs. 17%) and a trend towards increased liver enzyme elevations (47% vs. 39%).
Conclusions:
- Initiating MTX at 25 mg/week is associated with a higher incidence of minor toxicities compared to 15 mg/week.
- The observed toxicity profile suggests that MTX doses exceeding 15 mg/week can be safely explored for enhanced therapeutic benefit in RA.
- Higher initial MTX doses appear manageable with careful monitoring.